Collaboration With Industry And CMS Are Priorities For FDA’s Gottlieb
This article was originally published in The Gray Sheet
Executive Summary
The pressure of meeting MDUFMA premarket review deadlines has prevented FDA reviewers from having "as much interaction as they would like with companies," according to FDA Deputy Commissioner for Medical & Scientific Affairs Scott Gottlieb, MD
You may also be interested in...
FDA Premarket Activity Safe From Current Political Storm – Ex Chief Counsel
Current public pressure on the FDA in the wake of a string of high-profile safety problems for both drugs and devices will not make the agency more restrained in approving premarket applications, according to one former top FDA official
FDA Premarket Activity Safe From Current Political Storm – Ex Chief Counsel
Current public pressure on the FDA in the wake of a string of high-profile safety problems for both drugs and devices will not make the agency more restrained in approving premarket applications, according to one former top FDA official
“Passive” Adverse Event Data Inadequate, Say FDA/HRS Meeting Panelists
FDA must expand its "enhanced" adverse event reporting system and improve "passive" surveillance in order to detect rare device malfunctions, said panelists at the Policy Conference on Pacemaker and Implantable Cardioverter Defibrillator Performance in Washington, D.C. Sept. 16